Skip to main content

Table 2 Infection and treatment characteristics

From: Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study

 

Anidulafungin

Micafungin

P

(n = 30)

(n = 33)

Candida score at start

3 (2)

3 (3)

0.71

Source of isolatesa

  

0.25

 Blood

10 (33)

12 (36)

 

 Intra-abdominal fluid

17 (57)

20 (63)

 

 Pleural fluid

3 (10)

1 (3)

 

Candida spp. a

  

0.46

 Candida albicans

8 (27)

3 (9)

 

 Candida dublienis

0 (0)

2 (6)

 

 Candida glabrata

17 (57)

21 (66)

 

 Candida krusei

3 (10)

3 (10)

 

 Candida parapsilosis

1 (3)

2 (6)

 

 Candida tropicalis

1 (3)

2 (6)

 

Global responsea

21 (67)

23 (70)

0.80

Clinical responsea

24 (80)

28 (85)

0.62

Microbial responsea

21 (70)

24 (73)

0.81

 Gaining negative culturesa

18 (60)

20 (60)

0.96

Duration of infection (days)

3 (5)

3 (5)

0.80

Duration of treatment (days)

12 (8)

14 (9)

0.40

Length of ICU stay (days)

13 (15)

14 (21)

0.64

Mortality day 28 after starta

20 (67)

18 (55)

0.33

Mortality day 90 after starta

26 (87)

21 (64)

0.04

  1. Numbers (percentage) aor median (interquartile range), where appropriate
  2. Abbreviations: ICU intensive care unit